Insertion site inflammation was associated with central-line–associated bloodstream infections at a tertiary-care center, 2015–2018

Author(s):  
Takaaki Kobayashi ◽  
Gosia S. Clore ◽  
Mary E. Kukla ◽  
Mohammed Alzunitan ◽  
Jeffrey Kritzman ◽  
...  

Abstract There are currently no guidelines for central-line insertion site evaluation. Our study revealed an association between insertion site inflammation (ISI) and the development of central-line–associated bloodstream infections (CLABSIs). Automated surveillance for ISI is feasible and could help prevent CLABSI.

Author(s):  
Jennifer LeRose ◽  
Avnish Sandhu ◽  
Jordan Polistico ◽  
Joe Ellsworth ◽  
Mara Cranis ◽  
...  

Abstract A comparative retrospective study to quantify the impact of Coronavirus Disease 2019 (COVID-19) on patient safety. We found a statistically significant increase in central line-associated blood stream infections and blood culture contamination rates during the pandemic. Increased length of stay and mortality was also observed during COVID-19.


2011 ◽  
Vol 32 (6) ◽  
pp. 619-622 ◽  
Author(s):  
Aysegul Gozu ◽  
Colleen Clay ◽  
Faheem Younus

Despite increasing awareness of central line-associated bloodstream infections (CLABSIs) in general wards, published strategies come from intensive care units (ICUs) of large tertiary care centers. After implementing a central line insertion checklist, two community hospitals experienced an 86% reduction in CLABSI rates in ICUs and a 57% reduction in non-ICU settings over 36 months.


2015 ◽  
Vol 36 (1) ◽  
pp. 76-80 ◽  
Author(s):  
Yasuaki Tagashira ◽  
Yasuji Kozai ◽  
Hitomi Yamasa ◽  
Masako Sakurada ◽  
Tetsuya Kashiyama ◽  
...  

BACKGROUNDRapidly growing nontuberculous mycobacteria (RGM) are considered rare pathogens, causing central line–associated bloodstream infection. We identified an outbreak of central line–associated bloodstream infection due to RGM at a hematology-oncology ward during a 5-month period.DESIGNOutbreak investigation and literature review.SETTINGA Japanese tertiary care center.PATIENTSAdults who were hospitalized at the hematology-oncology ward from October 15, 2011, through February 17, 2012.RESULTSA total of 5 patients with a bloodstream infection due to RGM (4 cases ofMycobacterium mucogenicumand 1 case ofMycobacterium canariasenseinfection) were identified; of these, 3 patients had acute myeloid leukemia, 1 had acute lymphocytic leukemia, and 1 had aplastic anemia. Four of the 5 patients received cord blood transplantation prior to developing the bloodstream infection. All central venous catheters in patients with a bloodstream infection were removed. These patients promptly defervesced after catheter removal and their care was successfully managed without antimicrobial therapy. Surveillance cultures from the environment and water detectedM. mucogenicumandM. canariasensein the water supply of the hematology-oncology ward. The isolates from the bloodstream infection and water sources were identical on the basis of 16S-rRNA gene sequencing.CONCLUSIONSThe source of RGM in the outbreak of bloodstream infections likely was the ward tap water supply. Awareness of catheter-related bloodstream infections due to nontuberculous mycobacteria should be emphasized, especially where immunocompromised patients are at risk. Also, using antimicrobials after catheter removal to treat central line–associated bloodstream infection due to RGM may not be necessary.Infect Control Hosp Epidemiol 2015;36(1): 76–80


2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S156-S157
Author(s):  
Vidya Menon ◽  
Binny P P ◽  
Fabia E T ◽  
Sanjeev Singh ◽  
Keith S Kaye ◽  
...  

2020 ◽  
Vol 13 ◽  
pp. 117863372090597 ◽  
Author(s):  
M Bosaeed ◽  
A Ahmad ◽  
A Alali ◽  
E Mahmoud ◽  
L Alswidan ◽  
...  

Introduction: Multidrug-resistant Pseudomonas aeruginosa isolates have multiple resistance mechanisms, and there are insufficient therapeutic options to target them. Ceftolozane-tazobactam is a novel antipseudomonal agent that contains a combination of an oxyimino-aminothiazolyl cephalosporin (ceftolozane) and a β-lactamase inhibitor (tazobactam). Methods: A single-center retrospective observational study between January 2017 and December 2018 for patients who had been diagnosed with carbapenem-resistant P aeruginosa infections and treated with ceftolozane-tazobactam for more than 72 hours. We assessed clinical success based on microbiological clearance as well as the clinical resolution of signs and symptoms of infection. Results: A total of 19 patients fit the inclusion criteria, with a median age was 57 years, and 53% were female. The types of infections were nosocomial pneumonia, acute bacterial skin, and skin structure infections; complicated intra-abdominal infections; and central line–associated bloodstream infections. All of the isolates were resistant to both meropenem and imipenem. The duration of therapy was variable (average of 14 days). At day 14 of starting ceftolozane-tazobactam, 18 of 19 patients had a resolution of signs and symptoms of the infection. Only 14 of 19 patients (74%) had proven microbiological eradication observed at the end of therapy. During therapy, there was no adverse event secondary to ceftolozane-tazobactam, and no Clostridium difficile infection was identified. The 30-day mortality rate was 21% (4/19). Conclusions: Multidrug-resistant P aeruginosa infection is associated with high mortality, which would potentially be improved using a new antibiotic such as ceftolozane-tazobactam. Studies are required to explain the role of combination therapy, define adequate dosing, and identify the proper duration of treatment.


2020 ◽  
Vol 13 (11) ◽  
pp. 1694-1698
Author(s):  
Rasha S. Almahmoud ◽  
Maha A. Alfarhan ◽  
Walaa M. Alanazi ◽  
Farah K. Alhamidy ◽  
Hanan H. Balkhy ◽  
...  

2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Shruti K. Gohil ◽  
Jennifer Yim ◽  
Kathleen AQuan ◽  
Maurice Espinoza ◽  
Deborah Thompson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document